Nobuyuki Yamamoto

Nobuyuki Yamamoto

Auto-generated profile, based on publicly available information

Nobuyuki Yamamoto

Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
TSTakashi Seto
Takashi Seto
TKTerufumi Kato
Terufumi Kato
MNMakoto Nishio
Makoto Nishio
KGKoichi Goto
Koichi Goto
SAShinji Atagi
Shinji Atagi
NYNobuyuki Yamamoto
Nobuyuki Yamamoto

1 May 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
TTToshiaki Takahashi
Toshiaki Takahashi
TYTakeharu Yamanaka
Takeharu Yamanaka
TSTakashi Seto
Takashi Seto
HHHideyuki Harada
Hideyuki Harada
HNHiroshi Nokihara
Hiroshi Nokihara
NYNobuyuki Yamamoto
Nobuyuki Yamamoto

10 August 2010 in Journal of Clinical Oncology
Verified
Journal Article
Open access
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
YNYasumasa Nishimura
Yasumasa Nishimura
KTKayoko Tsujino
Kayoko Tsujino
MSMiyako Satouchi
Miyako Satouchi
MFMasahiro Fukuoka
Masahiro Fukuoka
Purpose: This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients with unresectable stage III non–small-cell lung cancer (NSCLC). Patients and Methods: Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m2 on day 1)/vindesine (3 mg/m2 on days 1, 8)/cisplatin (80 mg/m2 on day 1) plus TRT 60 Gy (treatment break for 1 week); B, weekly irinotecan (20 mg/m2)/carboplatin (area under the plasma concentration-time curve [AUC] 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m2 on days1, 8)/carboplatin (AUC 5 on day1); C, weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m2 on day1)/carboplatin (AUC 5 on day 1). Results: The median survival time and 5-year survival rates were 20.5, 19.8, and 22.0 months and 17.5%, 17.8%, and 19.8% in arms A, B, and C, respectively. Although no significant differences in overall survival were apparent among the treatment arms, noninferiority of the experimental arms was not achieved. The incidences of grade 3 to 4 neutropenia, febrile neutropenia, and gastrointestinal disorder were significantly higher in arm A than in arm B or C (P < .001). Chemotherapy interruptions were more common in arm B than in arm A or C. Conclusion: Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms. Arm C should be considered a standard regimen in the management of locally advanced unresectable NSCLC.

28 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMasahito Hosokawa
Masahito Hosokawa
HKHirotsugu Kenmotsu
Hirotsugu Kenmotsu
YKYasuhiro Koh
Yasuhiro Koh
TYTomoko Yoshino
Tomoko Yoshino
TYTakayuki Yoshikawa
Takayuki Yoshikawa
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, colon, and prostate cancer. However, poor sensitivity has been reported for non-small cell lung cancer (NSCLC). To address this problem, we developed a microcavity array (MCA) system integrated with a miniaturized device for CTC isolation without relying on EpCAM expression. Here, we report the results of a clinical study on CTCs of advanced lung cancer patients in which we compared the MCA system with the CellSearch system, which employs the conventional EpCAM-based method. Paired peripheral blood samples were collected from 43 metastatic lung cancer patients to enumerate CTCs using the CellSearch system according to the manufacturer’s protocol and the MCA system by immunolabeling and cytomorphological analysis. The presence of CTCs was assessed blindly and independently by both systems. CTCs were detected in 17 of 22 NSCLC patients using the MCA system versus 7 of 22 patients using the CellSearch system. On the other hand, CTCs were detected in 20 of 21 small cell lung cancer (SCLC) patients using the MCA system versus 12 of 21 patients using the CellSearch system. Significantly more CTCs in NSCLC patients were detected by the MCA system (median 13, range 0–291 cells/7.5 mL) than by the CellSearch system (median 0, range 0–37 cells/7.5 ml) demonstrating statistical superiority (p = 0.0015). Statistical significance was not reached in SCLC though the trend favoring the MCA system over the CellSearch system was observed (p = 0.2888). The MCA system also isolated CTC clusters from patients who had been identified as CTC negative using the CellSearch system. The MCA system has a potential to isolate significantly more CTCs and CTC clusters in advanced lung cancer patients compared to the CellSearch system.

1 March 2012 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
Tateaki NaitoTateaki Naito
Tateaki Naito
FTFumihiro Tanaka
Fumihiro Tanaka
AOAkira Ono
Akira Ono
KYKazue Yoneda
Kazue Yoneda
TTToshiaki Takahashi
Toshiaki Takahashi
NYNobuyuki Yamamoto
Nobuyuki Yamamoto

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
THToyoaki Hida
Toyoaki Hida
HNHiroshi Nokihara
Hiroshi Nokihara
MMMasahiro Morise
Masahiro Morise
KAKoichi Azuma
Koichi Azuma
TTTomohide Tamura
Tomohide Tamura